A farkon watan Maris, Hukumar Kula da Kayayyakin Lafiya ta Ƙasa ta amince da Jaypirca® (pirtobrutinib) don maganin manya da ke fama da cutar sankarar lymphocytic leukemia (CLL) ko ƙananan ƙwayoyin lymphocytic lymphoma (SLL) waɗanda suka sami aƙalla magani ɗaya a baya, gami da maganin hana ƙwayar cutar Bruton's tyrosine kinase (BTK).
Pirtobrutinib wani maganin hana kinesa ne mai zaɓi sosai wanda ke amfani da sabuwar hanyar ɗaurewa mara haɗin gwiwa don faɗaɗa fa'idar niyya ga hanyar BTK ga marasa lafiya na CLL/SLL da aka riga aka yi musu magani da maganin hana BTK mai haɗin gwiwa (ibrutinib, acalabrutinib, ko zanubrutinib). Pirtobrutinib ya sami amincewa daga Hukumar Abinci da Magunguna ta Amurka (FDA) a watan Janairun 2023 a matsayin maganin hana BTK mara haɗin gwiwa (mai juyawa). A watan Oktoban 2024, an amince da pirtobrutinib a China a matsayin maganin da ake amfani da shi na lokaci guda don magance manyan marasa lafiya da ke fama da cutar sankarar mahaifa mai dawowa ko kuma mai hana mantle cell lymphoma (MCL) waɗanda suka taɓa karɓar aƙalla magunguna biyu na tsarin da suka gabata, gami da maganin hana tyrosine kinase (BTK) na Bruton.
Amincewar wannan sabon alamar ta dogara ne akan sakamakon binciken BRUIN CLL 321 na duniya, mai cibiyoyi da yawa, bazuwar, na Mataki na 3. BRUIN CLL 321 shine gwajin Mataki na 3 na farko a duniya da aka gudanar a cikin marasa lafiya da ke fama da CLL/SLL waɗanda aka yi musu magani da maganin hana BTK mai haɗin gwiwa (cBTKi). Binciken ya yi rajistar jimillar marasa lafiya 238 kuma ya kimanta inganci da amincin maganin pirtobrutinib idan aka kwatanta da zaɓin mai bincike na IdelaR (idelalisib plus rituximab) ko BR (bendamustine plus rituximab). Sakamakon ya nuna cewa pirtobrutinib ya ɗauki tsawon lokaci mai tsawo a cikin rayuwa ta 'yanci (PFS) idan aka kwatanta da tsarin zaɓin mai binciken (watanni 14.0 vs watanni 8.7; rabon haɗari [HR] = 0.54). Bugu da ƙari, ƙimar dakatarwa saboda abubuwan da suka shafi sakamako masu illa da suka shafi magani ya yi ƙasa da ƙasa da amfani da pirtobrutinib (5.2% idan aka kwatanta da 21.1%), wanda hakan ya ƙara tabbatar da ingancinsa da fa'idodin juriyarsa ga marasa lafiya da aka yi wa magani da maganin hana BTK mai hana covalent.
Tuntube Mu Don Fara Tafiyar Fatarku
Sashen Duniya na Asibitin Oncology na Yankin Kudu na Beijing ya sadaukar da kai don samar wa marasa lafiya na duniya damar samun maganin cutar kansa mafi inganci. Idan kai ko wani ɗan uwa yana fuskantar cutar kansa kuma ba shi da isasshen amsa ga magungunan gargajiya, ƙungiyar Kula da Marasa Lafiya ta Duniya a shirye take ta samar muku da cikakkun bayanai da tsare-tsaren magani na musamman.
Da fatan za a tuntuɓe mu ta hanyoyin da ke ƙasa don ƙarin koyo game da zaɓuɓɓukan maganin ciwon daji:
- Waya: 400-880-3716
- WeChat: 17801183037
- Email: 100085_010@163.com or myimmnet@163.com (Emails are welcome, and we will respond promptly)
Sashen Duniya na Asibitin Kula da Cututtukan Cututtuka na Yankin Kudu na Beijing yana fatan yin hadin gwiwa da ku a yakin da ake yi da cutar kansa. Ko ina kuke a duniya, mun kuduri aniyar samar muku da mafi kyawun tallafin likita da kuma kulawa mai tausayi.
Take the first step towards overcoming your illness. Call us at 400-880-3716 or contact us via WeChat at 17801183037 today. You can also email us at 100085_010@163.com or myimmnet@163.com to schedule a one-on-one consultation with our team of experts.
Lokacin Saƙo: Maris-12-2026